Biocomposites, a global medical devices company known for its innovative solutions in bone and soft tissue infection management, has expanded its product range with the launch of SYNICEM spacers in the UK. This announcement follows the company's acquisition of French-based medical device manufacturer Synimed in 2022, known for its expertise in bone cement and polymer-related products.
SYNICEM spacers are designed to assist orthopaedic surgeons in the revision of hip, knee, and shoulder surgeries. Unlike traditional intra-operative moulded and handmade spacers, these antibiotic-loaded, preformed spacers address the challenges of maintaining articular space and aiding the treatment of infection. They are precision-engineered for consistency and structural uniformity, offering high local concentrations of gentamicin and saving surgeons’ time during procedures with their ready-to-use format and case-by-case flexibility.
Rohit Dhawan, a consultant orthopaedic surgeon, praises the practicality and versatility of SYNICEM spacers, emphasizing their readiness for use and suitability for various patient anatomies, leading to efficient procedures and infection-free outcomes for patients.
Michael Harris, CEO of Biocomposites, expressed enthusiasm about the addition of SYNICEM spacers to their product lineup. He highlighted the strategic acquisition of Synimed as a move that enriches their portfolio and supports surgeons in managing and treating infections. The introduction of SYNICEM spacers in the UK and into the broader Biocomposites network is a significant step in ensuring more patients benefit from these advanced medical solutions.
Antibiotic-Loaded Preformed Spacers
Biocomposites Recently Launched SYNICEMTM Spacers
Trend Themes
1. Antibiotic-loaded Preformed Spacers - The launch of SYNICEM spacers offers a disruptive innovation opportunity in bone and soft tissue infection management, providing orthopaedic surgeons with consistent and structurally uniform antibiotic-loaded spacers.
2. Precision-engineered Orthopedic Solutions - Biocomposites' expansion into precision-engineered spacers presents a disruptive innovation opportunity for the orthopedic industry, enabling more efficient procedures with ready-to-use, case-by-case flexible solutions.
3. Medical Device Acquisition - The acquisition of Synimed by Biocomposites provides a disruptive innovation opportunity in the medical device industry, enriching their portfolio with bone cement and polymer-related products for infection management.
Industry Implications
1. Medical Devices - The introduction of SYNICEM spacers into Biocomposites' product lineup creates a disruptive innovation opportunity in the medical devices industry, offering innovative solutions for bone and soft tissue infection management.
2. Orthopedics - The launch of SYNICEM spacers provides a disruptive innovation opportunity in the orthopedics industry, improving outcomes in hip, knee, and shoulder revision surgeries with precision-engineered, antibiotic-loaded spacers.
3. Bone Cement Manufacturing - The strategic acquisition of Synimed by Biocomposites creates a disruptive innovation opportunity in the bone cement manufacturing industry, combining expertise to develop advanced solutions for infection management.